| http://purl.uniprot.org/citations/27509063 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/27509063 | http://www.w3.org/2000/01/rdf-schema#comment | "It is now widely accepted that therapeutic antibodies targeting epidermal growth factor receptor (EGFR) can have efficacy in KRAS wild-type advanced colorectal cancer (CRC) patients. What remains to be ascertained is whether a subgroup of KRAS-mutated CRC patients might not also derive benefit from EGFR inhibitors. Metalloproteinase inhibitor 1 (TIMP-1) is a pleiotropic factor predictive of survival outcome of CRC patients. Levels of TIMP-1 were measured in pre-treatment plasma samples (n = 426) of metastatic CRC patients randomized to Nordic FLOX (5-fluorouracil and oxaliplatin) +/-cetuximab (NORDIC VII study). Multivariate analysis demonstrated a significant interaction between plasma TIMP-1 protein levels, KRAS status and treatment with patients bearing KRAS mutated tumors and high TIMP-1 plasma level (> 3rd quartile) showing a significantly longer overall survival if treated with cetuximab (HR, 0.48; 95% CI, 0.25 to 0.93). To gain mechanistic insights into this association we analyzed a set of five different CRC cell lines. We show here that EGFR signaling induces TIMP-1 expression in CRC cells, and that TIMP-1 promotes a more aggressive behavior, specifically in KRAS mutated cells. The two sets of data, clinical and in vitro, are complementary and support each other, lending strength to our contention that TIMP-1 plasma levels can identify a subset of patients with KRAS-mutated metastatic CRC that will have benefit from EGFR-inhibition therapy."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.org/dc/terms/identifier | "doi:10.18632/oncotarget.11118"xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Brunner N."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Tveit K.M."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Pfeiffer P."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Nordgaard C."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Christensen I.J."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Nielsen H.J."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Moreira J.M."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Guren T.K."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Kure E.H."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Glimelius B."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Ikdahl T."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Sorbye H."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Tarpgaard L.S."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Noer J."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/author | "Orum-Madsen M.S."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/date | "2016"xsd:gYear |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/name | "Oncotarget"xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/pages | "59441-59457"xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/title | "TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer."xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://purl.uniprot.org/core/volume | "7"xsd:string |
| http://purl.uniprot.org/citations/27509063 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/27509063 |
| http://purl.uniprot.org/citations/27509063 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/27509063 |